🔹 Adj. EPS: $1.88 🟢 vs $1.64 est
🔹 Revenue: $5.74B 🟢 vs. $5.59B est
🔹 Free Cash Flow (non-GAAP): $1.1B
Guidance
🔹 FY25 Adj. EPS: $7.60–$7.75 🟡 vs. $7.67 est midpoint
🔹 Q2'25 Core Revenue Growth: Low-single digits YoY
🔹 FY25 Core Revenue Growth: ~3% YoY (no change)
CEO Commentary
🔸 “Revenue, earnings, and cash flow exceeded expectations—driven by momentum in bioprocessing and better-than-expected respiratory demand in molecular diagnostics.” — Rainer M. Blair, CEO
